ESCRS - PO0893 - The Effect Of Benozzi Method Treatment For Presbyopia On Automated Perimetry

The Effect Of Benozzi Method Treatment For Presbyopia On Automated Perimetry

Published 2023 - 41st Congress of the ESCRS

Reference: PO0893 | Type: Free paper | DOI: 10.82333/1skg-sq81

Authors: Giovanna Benozzi* 1 , Juliana Leiro 1 , Betina Orman 2

1Centro de Investigación Avanzada de la Presbicia,Buenos Aires,Argentina, 2Universidad de Buenos Aires. Facultad de Odontología. Cátedra de Farmacología,Buenos Aires,Argentina

Purpose

To evaluate the effects of the Benozzi Method treatment with eye drops for presbyopia on perimetry in presbyopic patients.

Setting

Benozzi Method pharmacological treatment for presbyopia is a proven option for emmetropic patients, to improve near and far-distance visual acuity. Therefore, perimetry evaluation is necessary for patients' safety.

Methods

Twenty-four eyes of 12 emmetropic presbyopic patients (between 40 and 55 years old) underwent perimetry (Octopus 600 perimeter) before and after eye-drop instillation of Benozzi Method treatment (pilocarpine and diclofenac). A baseline examination was performed, including refraction, visual acuity, slit-lamp examination, pupillary measurement, and fundus evaluation. The results were compared using the paired Student's t-test.

Results

The average pupil size in the normal condition was 5.3 ± 0.6 mm, and it decreased to 3.1 ± 0.6 mm after drop instillation (p<0.0001). The mean defect (MD) and pattern standard deviation (PSD) did not change before and after instillation of the eye-drop. Baseline, the MD was -1.390 0.45 and PSD 1.120  0.13 and after drop instillation MD was -1.55  0.51 and PSD 1.190  0.13 (p=0.28 and p=0.11, respectively).

Conclusions

In emmetropic presbyopic patients treated with drops of Benozzi Method treatment for presbyopia, no significant differences were observed in perimetry before and after the instillation of the drop. Considering that there was a reduction in the average pupil size, this result is relevant for the safety of patients treated pharmacologically for presbyopia.